1-Guanylbenzotriazol | 19503-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1-Guanylbenzotriazol
• 英文别名: benzotriazole-1-carboximidic acid amide；1H-Benzotriazole-1-carboximidamide；benzotriazole-1-carboximidamide
• CAS: 19503-25-4
• 化学式: C₇H₇N₅
• 分子量: 161.166
• InChiKey: PYLUJEDSEQRWTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-Guanylbenzotriazol 以68%的产率得到
  参考文献：
  名称：

  Katritzky Alan R., Parris Roslyn L., Allin Steven M., Steel Peter J., Synth. Commun., 25 (1995) N 8, S 1173- 1186

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲基-2-疏基硫酸脲 、 T406石油添加剂 在 三乙胺 、 mercury dichloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-Guanylbenzotriazol
  参考文献：
  名称：

  WO2024159162A1

  摘要：

  公开号：

文献信息

• METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY
  申请人：Jnana Therapeutics, Inc.

  公开号：US20210299070A1

  公开（公告）日：2021-09-30

  Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type creatine transporter. Also disclosed are methods of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier of a mammal, and methods of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a mammalian cell.

  揭示了治疗肌酸转运蛋白缺乏症的方法，包括向需要的哺乳动物施用增加突变型或野生型肌酸转运蛋白对底物转运的化合物的治疗有效量。还披露了增加鸟氨酸乙酸或其盐跨越哺乳动物血脑屏障的方法，以及减少哺乳动物细胞中鸟氨酸乙酸或其盐的积累或浓度的方法。
• N,N+hu 1 +l SUBSTITUTED PIPERAZINES HAVING COMBINED ANTIAGGREGANT, ANTICOAGULANT AND VASODILATORY ACTIVITY, AND METHOD FOR PRODUCING SAME
  申请人：Veselkina Olga Sergejevna

  公开号：US20130267707A1

  公开（公告）日：2013-10-10

  The invention relates to derivatives of N,N′-substituted piperazines of the general formula (I): where R 1 and R 2 denote linear or branched (C 1 -C 4 )alkyl, linear or branched (C 1 -C 4 )alkoxy, CH 3 C(═O)O or halogen; n=1-5; m=0-3; Z denotes CH 2 , C═O or SO 2 ; X denotes C(═NH)NH 2 , C(═NH)NHC(═NH)NH 2 or CH 2 (CHR 3 ) p CH 2 SO 3 H, where R 3 denotes H, OH, CH 3 C(═O)O or HOSO 2 O and p=0-1; and G denotes low-molecular-weight organic or mineral acid, sodium, potassium or ammonium cations, or water. Said derivatives have antiaggregant, anticoagulant and vasodilatory properties. The invention further relates to a method for producing said derivatives by reacting N-substituted piperazines either with carboxamide amidating agents or salts thereof, or with haloalkyl sulfonic acids or salts thereof in organic solvents or in water in the presence of bases. The compounds may be used for the prophylaxis and treatment of disorders of the hemostatic system.

  该发明涉及一般式（I）的N,N′-取代哌嗪衍生物，其中R1和R2表示线性或支链（C1-C4）烷基，线性或支链（C1-C4）烷氧基，CH3C(═O)O或卤素；n=1-5；m=0-3；Z表示CH2，C═O或SO2；X表示C(═NH)NH2，C(═NH)NHC(═NH)NH2或CH2(CHR3)pCH2SO3H，其中R3表示H，OH，CH3C(═O)O或HOSO2O，p=0-1；G表示低分子量有机或矿物酸，钠，钾或铵阳离子，或水。所述衍生物具有抗凝、抗凝血和扩血管作用。该发明还涉及一种通过将N-取代哌嗪与羧酰胺化剂或其盐，或卤代烷磺酸或其盐在有机溶剂或水中在碱的存在下反应而制备所述衍生物的方法。这些化合物可用于预防和治疗止血系统疾病。
• SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS
  申请人：Jnana Therapeutics, Inc.

  公开号：US20210371403A1

  公开（公告）日：2021-12-02

  Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein.

  揭示了用于治疗或预防与蛋白质突变相关的疾病或障碍的化合物、组合物和方法。
• Derivatives of morphine-like opioid compounds
  申请人：——

  公开号：US20040242616A1

  公开（公告）日：2004-12-02

  The present disclosure concerns compounds of formula (I) and pharmaceutically acceptable salts, hydrates, solvates, pharmaceutically acceptable derivatives, pro-drugs, tautomers and/or isomers thereof. The disclosure also relates to processes for the preparation of compounds according to formula (I), pharmaceutical or veterinary compositions containing such compounds or methods of treatment and/or prophylaxis of a condition or symptom that is inhibited, reduced or alleviated by opioid receptor activation. 1

  本公开涉及式(I)的化合物及其药学上可接受的盐、水合物、溶剂物、药学上可接受的衍生物、前药、互变异构体和/或同分异构体。该公开还涉及根据式(I)制备化合物的方法，包含这样的化合物的药物或兽药组合物或通过阿片受体激活抑制、减少或缓解症状或状态的治疗和/或预防方法。
• Bi-directional synthesis of oligoguanidine transport agents
  申请人：Wender A. Paul

  公开号：US20060264608A1

  公开（公告）日：2006-11-23

  Synthesis routes that can be adapted to large scale synthesis of oligoguanidine compounds such as oligoarginine compounds are described which use a perguanidinylation step to convert a group of ω-amino groups to the corresponding guanidinyl groups. These compounds find utility as transport agents. Modified oligoguanidine compounds are also described.

  本文描述了可用于大规模合成寡聚胍类化合物，如寡聚精氨酸化合物的合成路线，其中使用一步过氧胍基化反应将一组ω-氨基基团转化为相应的胍基基团。这些化合物被用作运输剂。还描述了改性的寡聚胍类化合物。